Abstract
e12598Background: NCCN (National comprehensive cancer network) recommends to consider Oncotype DX testing for patients diagnosed with stage IA breast cancers between 0.5- 1 cm that are hormone receptor positive and HER-2 negative. This study is a retrospective review of patients diagnosed with T1b stage IA breast cancers diagnosed at Cone Health Cancer Center between 2012 and 2017 who had Oncotype DX testing. Methods: Patients with T1b hormone receptor positive and HER-2 negative breast cancer, who had Oncotype DX testing performed were queried from tumor registry from 2012 to 2017. The registry also provided information regarding the grade and whether these patients received chemotherapy. Results: A total of 73 patients with T1b N0 (stage IA ) invasive breast cancers that were ER and PR positive and HER-2 negative between 2012 and 2017, had Oncotype DX test performed. Along these, 12 patients received adjuvant chemotherapy. Among those patients receiving adjuvant chemotherapy, 9 patients had Oncotype DX ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
